Logo image of MRSN

MERSANA THERAPEUTICS INC (MRSN) Stock Fundamental Analysis

USA - NASDAQ:MRSN - US59045L2051 - Common Stock

9.58 USD
+0.28 (+3.01%)
Last: 10/31/2025, 4:10:09 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MRSN. MRSN was compared to 534 industry peers in the Biotechnology industry. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative. MRSN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MRSN had negative earnings in the past year.
MRSN had a negative operating cash flow in the past year.
In the past 5 years MRSN always reported negative net income.
MRSN had a negative operating cash flow in each of the past 5 years.
MRSN Yearly Net Income VS EBIT VS OCF VS FCFMRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -87.54%, MRSN is not doing good in the industry: 72.47% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.54%
ROE N/A
ROIC N/A
ROA(3y)-61.62%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRSN Yearly ROA, ROE, ROICMRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRSN Yearly Profit, Operating, Gross MarginsMRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K

More info and screens

1

2. Health

2.1 Basic Checks

MRSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRSN has less shares outstanding
Compared to 5 years ago, MRSN has more shares outstanding
The debt/assets ratio for MRSN is higher compared to a year ago.
MRSN Yearly Shares OutstandingMRSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
MRSN Yearly Total Debt VS Total AssetsMRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MRSN has an Altman-Z score of -17.53. This is a bad value and indicates that MRSN is not financially healthy and even has some risk of bankruptcy.
MRSN has a Altman-Z score of -17.53. This is amonst the worse of the industry: MRSN underperforms 82.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.53
ROIC/WACCN/A
WACC10.51%
MRSN Yearly LT Debt VS Equity VS FCFMRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MRSN has a Current Ratio of 1.35. This is a normal value and indicates that MRSN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.35, MRSN is not doing good in the industry: 82.96% of the companies in the same industry are doing better.
A Quick Ratio of 1.35 indicates that MRSN should not have too much problems paying its short term obligations.
The Quick ratio of MRSN (1.35) is worse than 82.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35
MRSN Yearly Current Assets VS Current LiabilitesMRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

MRSN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -161.54%.
The Revenue has grown by 16.13% in the past year. This is quite good.
The Revenue has been decreasing by -0.78% on average over the past years.
EPS 1Y (TTM)-161.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.6%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y904.13%
Revenue growth 5Y-0.78%
Sales Q2Q%33.28%

3.2 Future

The Earnings Per Share is expected to grow by 7.99% on average over the next years.
MRSN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.52% yearly.
EPS Next Y12.56%
EPS Next 2Y-2.38%
EPS Next 3Y-1.03%
EPS Next 5Y7.99%
Revenue Next Year-18.41%
Revenue Next 2Y-20.28%
Revenue Next 3Y-28.78%
Revenue Next 5Y32.52%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRSN Yearly Revenue VS EstimatesMRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
MRSN Yearly EPS VS EstimatesMRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRSN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRSN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRSN Price Earnings VS Forward Price EarningsMRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRSN Per share dataMRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.38%
EPS Next 3Y-1.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERSANA THERAPEUTICS INC

NASDAQ:MRSN (10/31/2025, 4:10:09 PM)

9.58

+0.28 (+3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners61.93%
Inst Owner Change-1.65%
Ins Owners1.61%
Ins Owner Change0.01%
Market Cap47.80M
Revenue(TTM)34.77M
Net Income(TTM)-74037000
Analysts86.67
Price Target74.31 (675.68%)
Short Float %6.19%
Short Ratio4.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.78%
Min EPS beat(2)-21.54%
Max EPS beat(2)3.98%
EPS beat(4)3
Avg EPS beat(4)16.3%
Min EPS beat(4)-21.54%
Max EPS beat(4)49.71%
EPS beat(8)6
Avg EPS beat(8)11.95%
EPS beat(12)7
Avg EPS beat(12)-39.65%
EPS beat(16)8
Avg EPS beat(16)-35.45%
Revenue beat(2)0
Avg Revenue beat(2)-53.34%
Min Revenue beat(2)-53.77%
Max Revenue beat(2)-52.91%
Revenue beat(4)2
Avg Revenue beat(4)16.57%
Min Revenue beat(4)-53.77%
Max Revenue beat(4)108.93%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-18.12%
Revenue beat(16)5
Avg Revenue beat(16)-7.85%
PT rev (1m)0%
PT rev (3m)1357.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1027.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-1355.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)120.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)11.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.62
EYN/A
EPS(NY)-10.65
Fwd EYN/A
FCF(TTM)-15.98
FCFYN/A
OCF(TTM)-15.98
OCFYN/A
SpS6.97
BVpS-10.65
TBVpS-10.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.62%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z -17.53
F-Score3
WACC10.51%
ROIC/WACCN/A
Cap/Depr(3y)129.19%
Cap/Depr(5y)101.94%
Cap/Sales(3y)4.83%
Cap/Sales(5y)339.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-161.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.6%
EPS Next Y12.56%
EPS Next 2Y-2.38%
EPS Next 3Y-1.03%
EPS Next 5Y7.99%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y904.13%
Revenue growth 5Y-0.78%
Sales Q2Q%33.28%
Revenue Next Year-18.41%
Revenue Next 2Y-20.28%
Revenue Next 3Y-28.78%
Revenue Next 5Y32.52%
EBIT growth 1Y30.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.82%
OCF growth 3YN/A
OCF growth 5YN/A

MERSANA THERAPEUTICS INC / MRSN FAQ

What is the fundamental rating for MRSN stock?

ChartMill assigns a fundamental rating of 1 / 10 to MRSN.


Can you provide the valuation status for MERSANA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MERSANA THERAPEUTICS INC (MRSN). This can be considered as Overvalued.


How profitable is MERSANA THERAPEUTICS INC (MRSN) stock?

MERSANA THERAPEUTICS INC (MRSN) has a profitability rating of 0 / 10.